Analysts Recommend “Hold” for Medpace Holdings Amid Market Activity

Shares of Medpace Holdings, Inc. (NASDAQ: MEDP) have received a consensus recommendation of “Hold” from analysts, according to a report by MarketBeat.com. The assessment comes from seventeen ratings firms currently covering the company, with four analysts advising to sell, ten recommending to hold, two suggesting a buy, and one issuing a strong buy recommendation.

The average twelve-month price target among brokerages that have reviewed the stock in the past year stands at $490.82. Recent analyst reports have varied in their outlook, indicating a mix of cautious and optimistic sentiments about the company’s future performance.

Recent Analyst Ratings and Price Targets

On October 24, Cowen reaffirmed a sell rating on Medpace shares. Following this, on October 27, Truist Financial set a price objective of $555.00 for the stock. In contrast, Weiss Ratings upgraded its assessment of Medpace to a buy (b) rating on the same day. BMO Capital Markets also began its coverage on November 13, issuing a market perform rating and a target price of $600.00. Notably, Zacks Research upgraded Medpace from a hold rating to a strong buy on October 27.

Medpace’s latest quarterly earnings results were published on October 22, revealing earnings per share (EPS) of $3.86, exceeding analysts’ expectations of $3.50 by $0.36. The company reported revenue of $659.90 million, surpassing estimates of $640.49 million, and marking a 23.7% increase compared to the same quarter last year. Medpace also announced its fiscal year 2025 guidance, projecting EPS between $14.60 and $14.86, while analysts expect the company to report an EPS of $12.29 for the current year.

Insider Transactions and Institutional Activity

In addition to analyst activities, insider trading has also garnered attention. On November 21, Chief Financial Officer Kevin M. Brady sold 3,000 shares of the company’s stock at an average price of $590.35, totaling $1,771,050.00. Following this transaction, Brady’s direct ownership in Medpace decreased to 6,000 shares, valued at approximately $3,542,100. Similarly, CEO August J. Troendle sold 668 shares on December 3 for around $394,580.92, resulting in a slight reduction of his holdings to 646,184 shares.

During the last quarter, insiders collectively sold 387,925 shares valued at $233,386,647. Currently, insiders hold 20.30% of the company’s stock.

Several institutional investors have also adjusted their positions in Medpace. Fifth Third Wealth Advisors LLC raised its stake by 2.6% in the third quarter, now owning 737 shares worth $379,000. BOKF NA increased its holdings by 0.8%, acquiring 2,542 shares valued at $1,307,000. Other firms, including HighPoint Advisor Group LLC and Portside Wealth Group LLC, have also expanded their stakes in the company.

As it stands, institutional investors and hedge funds collectively own 77.98% of Medpace’s stock. The company, a global contract research organization (CRO), supports clinical trials and offers a range of services designed to expedite the development of new therapies for the biotechnology, pharmaceutical, and medical device sectors.